Business Context and Reporting Period
This Form 8-K was filed by Miragen Therapeutics, Inc. (not Viridian Therapeutics, Inc.) on October 1, 2018. The registrant is a Delaware corporation headquartered in Boulder, Colorado, and is classified as an emerging growth company. The filing serves as a Regulation FD disclosure regarding a press release issued on the same date.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a scientific data presentation and does not contain financial statements or operational metrics.
Material Changes
There are no material financial changes reported in this filing. The significant event is the presentation of preclinical data for the company's product candidate, remlarsen (MRG-201), a microRNA-29 mimic. The data, presented at the 2018 Oligonucleotide Therapeutics Society annual OLIGO meeting in Seattle, demonstrated potential anti-fibrotic effects in the cornea of rats.
Guidance, Outlook, and Risks
- Management Commentary: The company highlighted the potential of remlarsen based on the preclinical rat study results.
- Legal Status of Information: The information contained in this Item 7.01 and the attached press release (Exhibit 99.1) is explicitly not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and shall not be incorporated by reference into any other SEC filings.
- Risks: The filing does not explicitly list new risks, though the data presented is preclinical and subject to the inherent risks of drug development.
Investor Verification Checklist
- Verify the company name is Miragen Therapeutics, Inc., not Viridian Therapeutics, Inc.
- Review the attached press release (Exhibit 99.1) for full details on the remlarsen preclinical study.
- Confirm that this 8-K does not contain updated financial guidance or liquidity data.
- Note that the scientific data presented is from animal studies (rats) and does not guarantee clinical success in humans.